Loading...

ARQT ARCUTIS BIOTHERAPEUTICS INC Management Changes 8-K Filing

RCTS

RQT

ARCUTIS BIOTHERAPEUTICS INC

(ARQT)

2025 8-K

Show Summary

Show Summary

Financial Statements

Management Change

Financial Results

Revenue Announcement

Financial Results

Financial Results

Annual Meeting of Stockholders

Earnings Reports

Appointment of CFO

Public Offering

License Agreement with Sato...

Earnings Reports

Stock Option Exchange Program

Option Exchange Program

Financial Results Press Rel...

Public Offering

Financial Results

Resignation of CFO

License Agreement with Hang...

Earnings Reports

Annual Meeting of Stockholders

Resignation of Senior VP

Earnings Reports

Earnings Reports

External Links:

On April 10, 2025, Arcutis Biotherapeutics appointed Latha Vairavan as the new CFO, succeeding David Topper, who will retire on May 15, 2025, with Vairavan receiving a salary of $450,000 and a bonus target of 45%. Vairavan's compensation includes stock options and a severance agreement providing benefits in case of termination without cause.

AI Assistant

ARCUTIS BIOTHERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.